State Key Laboratory of Natural Medicines, Department of TCMs Pharmaceuticals, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, 211198, PR China.
Yangtze River Pharmaceutical Group Beijing Haiyan Pharmaceutical Co., Ltd., Beijing, 102206, PR China; Beijing University of Chemical Technology, Beijing, 100029, PR China.
J Ethnopharmacol. 2021 May 10;271:113827. doi: 10.1016/j.jep.2021.113827. Epub 2021 Jan 16.
Suhuang antitussive capsule (Suhuang), one of traditional antitussive Chinese patent medicines, has been used for the treatment of post-infectious cough and cough variant asthma in clinical practice. It has been demonstrated to show numerous biological actions including antitussive and anti-inflammatory effects.
This study aims to investigate the effects of Suhuang on non-resolving inflammation and its underlying molecular mechanism.
In vitro, mitochondrial membrane potential and ROS were detected by flow cytometry analysis. mtDNA release and mPTP fluorescence were determined by Q-PCR and fluorescence microplate reader analysis. Cytochrome C release and 8-OHdG levels were evaluated by ELISA. Additionally, the effects of Suhuang on Drp1, MMP9, IκBα/NF-κB and NLRP3/ASC/Caspase-1 expression were determined by Q-PCR, gelatin zymography or immunoblot analysis. In vivo, C57/BL6 mice were orally administrated for 2 weeks with Suhuang, then lung injury was induced by LPS. Inflammatory mediators mRNA, histological assessment and NF-κB/Caspase-1/IL-1β levels were evaluated by Q-PCR, H&E staining and immunoblot analysis. Two sepsis models of mice were further used to evaluate its anti-inflammatory effects.
Suhuang restored mitochondrial homeostasis by inhibiting Drp1 activation and mitochondrial fission. Besides, Suhuang reduced mPTP opening, mitochondrial membrane potential collapse, ROS overproduction and mtDNA release. Moreover, Suhuang down-regulated MMP9 expression. As a consequence of preserved mitochondrial homeostasis, Suhuang inhibited NF-κB pathway activation by prevention of NF-κB-p65 phosphorylation and IκBα degradation. Suhuang also limited NLRP3 inflammasome activation by blocking NLRP3-ASC interaction and promoting NLRP3 ubiquitination degradation. Drp1 knockdown in vitro diminished the inhibitory effects of Suhuang on inflammatory responses, indicating the essential role of Drp1 in the Suhuang's activity. Consistently, the therapeutic effects of Suhuang were confirmed in LPS-inhaled mice, which recapitulated the protective actions of Suhuang in mitochondrial homeostasis in vitro. Additionally, two sepsis models of mice confirmed the inhibitory effects of Suhuang on uncontrolled inflammation.
Altogether, our work reveals that Suhuang inhibits non-resolving inflammation through inhibition of NF-κB signaling and NLRP3 inflammasome activation by preserving mitochondrial homeostasis, providing new pharmacological data for the clinical use of Suhuang. Our study also suggests mitochondrial homeostasis as a potential intrinsic regulatory strategy for treating inflammatory diseases.
苏黄止咳胶囊(苏黄)是一种传统的止咳中药专利药,已在临床实践中用于治疗感染后咳嗽和咳嗽变异性哮喘。它已被证明具有多种生物学作用,包括镇咳和抗炎作用。
本研究旨在探讨苏黄对未解决炎症的影响及其潜在的分子机制。
在体外,通过流式细胞术分析检测线粒体膜电位和 ROS。通过 Q-PCR 和荧光微孔板读数分析测定 mtDNA 释放和 mPTP 荧光。通过 ELISA 评估细胞色素 C 释放和 8-OHdG 水平。此外,通过 Q-PCR、明胶酶谱或免疫印迹分析测定苏黄对 Drp1、MMP9、IκBα/NF-κB 和 NLRP3/ASC/Caspase-1 表达的影响。在体内,用苏黄灌胃 C57/BL6 小鼠 2 周,然后用 LPS 诱导肺损伤。通过 Q-PCR、H&E 染色和免疫印迹分析评估炎症介质 mRNA、组织学评估和 NF-κB/Caspase-1/IL-1β 水平。进一步使用两种小鼠脓毒症模型评估其抗炎作用。
苏黄通过抑制 Drp1 激活和线粒体分裂来恢复线粒体动态平衡。此外,苏黄减少了 mPTP 开放、线粒体膜电位崩溃、ROS 产生过多和 mtDNA 释放。此外,苏黄下调了 MMP9 的表达。由于线粒体动态平衡得以维持,苏黄通过抑制 NF-κB-p65 磷酸化和 IκBα 降解来抑制 NF-κB 通路的激活。苏黄还通过阻断 NLRP3-ASC 相互作用和促进 NLRP3 泛素化降解来限制 NLRP3 炎性小体的激活。体外 Drp1 敲低削弱了苏黄对炎症反应的抑制作用,表明 Drp1 在苏黄活性中起关键作用。一致地,苏黄在 LPS 吸入小鼠中的治疗效果证实了苏黄在体外维持线粒体动态平衡的保护作用。此外,两种小鼠脓毒症模型证实了苏黄对失控性炎症的抑制作用。
总之,我们的工作表明,苏黄通过抑制 NF-κB 信号通路和 NLRP3 炎性小体的激活来抑制未解决的炎症,通过维持线粒体动态平衡为苏黄的临床应用提供了新的药理学数据。我们的研究还表明,线粒体动态平衡是治疗炎症性疾病的一种潜在内在调节策略。